|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007138,
umls-concept:C0008976,
umls-concept:C0045093,
umls-concept:C0079083,
umls-concept:C0086418,
umls-concept:C0144576,
umls-concept:C0205179,
umls-concept:C0205390,
umls-concept:C0242275,
umls-concept:C0728747,
umls-concept:C1274040,
umls-concept:C1513882
|
|
pubmed:issue |
16
|
|
pubmed:dateCreated |
2007-5-31
|
|
pubmed:abstractText |
We investigated the safety and efficacy (response rates, time to disease progression, survival) of trastuzumab, carboplatin, gemcitabine, and paclitaxel in advanced urothelial carcinoma patients and prospectively evaluated human epidermal growth factor receptor-2 (Her-2/neu) overexpression rates.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Carboplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:ChattaGurkamal SGS,
pubmed-author:ChenHelenH,
pubmed-author:DunnRodney LRL,
pubmed-author:GlodeL MichaelLM,
pubmed-author:HussainMaha H AMH,
pubmed-author:LaraPrimo NPNJr,
pubmed-author:MacVicarGary RGR,
pubmed-author:NanusDavid MDM,
pubmed-author:National Cancer Institute,
pubmed-author:PetrylakDaniel PDP,
pubmed-author:SmithDavid CDC,
pubmed-author:TrumpDonald LDL,
pubmed-author:VaishampayanUlkaU
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2218-24
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17538166-Adult,
pubmed-meshheading:17538166-Aged,
pubmed-meshheading:17538166-Aged, 80 and over,
pubmed-meshheading:17538166-Antibodies, Monoclonal,
pubmed-meshheading:17538166-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17538166-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17538166-Carboplatin,
pubmed-meshheading:17538166-Deoxycytidine,
pubmed-meshheading:17538166-Female,
pubmed-meshheading:17538166-Humans,
pubmed-meshheading:17538166-Immunohistochemistry,
pubmed-meshheading:17538166-Male,
pubmed-meshheading:17538166-Middle Aged,
pubmed-meshheading:17538166-Paclitaxel,
pubmed-meshheading:17538166-Prospective Studies,
pubmed-meshheading:17538166-Receptor, Epidermal Growth Factor,
pubmed-meshheading:17538166-Receptor, erbB-2,
pubmed-meshheading:17538166-Urinary Bladder Neoplasms
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.
|
|
pubmed:affiliation |
University of Michigan, Ann Arbor, USA. mahahuss@umich.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
